We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS SEEKS PEDIATRIC EXCLUSIVITY ON DRUG FACING GENERIC COMPETITION
BMS SEEKS PEDIATRIC EXCLUSIVITY ON DRUG FACING GENERIC COMPETITION
March 31, 2004
Aiming to ward off generic competition by an additional six months, Bristol-Myers Squibb (BMS) yesterday filed data with the FDA from two clinical studies involving the pediatric use of its profitable cancer drug Paraplatin (carboplatin).